Arcutis Biotherapeutics Stock Performance
| ARQT Stock | USD 13.81 0.98 7.64% |
Arcutis Biotherapeutics has a performance score of 2 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.3, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Arcutis Biotherapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Arcutis Biotherapeutics is expected to be smaller as well. Arcutis Biotherapeutics right now shows a risk of 4.86%. Please confirm Arcutis Biotherapeutics value at risk, and the relationship between the standard deviation and kurtosis , to decide if Arcutis Biotherapeutics will be following its price patterns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Arcutis Biotherapeutics are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating basic indicators, Arcutis Biotherapeutics may actually be approaching a critical reversion point that can send shares even higher in April 2025. ...more
Actual Historical Performance (%)
One Day Return (6.28) | Five Day Return (3.10) | Year To Date Return (11.88) | Ten Year Return (41.15) | All Time Return (41.15) |
1 | Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 12/06/2024 |
2 | Disposition of 1691 shares by Burnett Patrick of Arcutis Biotherapeutics at 14.0 subject to Rule 16b-3 | 12/31/2024 |
3 | Disposition of 12500 shares by Matthew Moore of Arcutis Biotherapeutics at 28.72 subject to Rule 16b-3 | 01/30/2025 |
4 | Disposition of 2173 shares by Edwards Larry Todd of Arcutis Biotherapeutics at 12.7 subject to Rule 16b-3 | 02/03/2025 |
5 | Insider Sell Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics Inc | 02/05/2025 |
6 | Suvretta Capital Management, LLC Reduces Holdings in Kura Oncology Inc | 02/14/2025 |
7 | Arcutis Biotherapeutics Inc to Participate in TD Cowen 45th Annual Health Care Conference | 02/19/2025 |
8 | Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE Cream 0.05 percent in Children 2 to 5 Years Old with Mild to Moderate... | 02/24/2025 |
9 | Arcutis Biotherapeutics Inc Q4 2024 Earnings EPS Loss of 0. ... | 02/25/2025 |
10 | Mizuho Raises Arcutis Biotherapeutics Price Target to 21.00 | 02/26/2025 |
11 | Arcutis Biotherapeutics, Inc. Just Reported Yearly Earnings Have Analysts Changed Their Mind On The Stock | 02/28/2025 |
| Begin Period Cash Flow | 89.3 M |
Arcutis |
Arcutis Biotherapeutics Relative Risk vs. Return Landscape
If you would invest 1,261 in Arcutis Biotherapeutics on December 4, 2024 and sell it today you would earn a total of 22.00 from holding Arcutis Biotherapeutics or generate 1.74% return on investment over 90 days. Arcutis Biotherapeutics is currently generating 0.144% in daily expected returns and assumes 4.8623% risk (volatility on return distribution) over the 90 days horizon. In different words, 43% of stocks are less volatile than Arcutis, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Arcutis Biotherapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Arcutis Biotherapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Arcutis Biotherapeutics, and traders can use it to determine the average amount a Arcutis Biotherapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0296
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | ARQT | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.86 actual daily | 43 57% of assets are more volatile |
Expected Return
| 0.14 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Arcutis Biotherapeutics is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Arcutis Biotherapeutics by adding it to a well-diversified portfolio.
Arcutis Biotherapeutics Fundamentals Growth
Arcutis Stock prices reflect investors' perceptions of the future prospects and financial health of Arcutis Biotherapeutics, and Arcutis Biotherapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Arcutis Stock performance.
| Return On Equity | -1.14 | ||||
| Return On Asset | -0.23 | ||||
| Profit Margin | (0.71) % | ||||
| Operating Margin | (0.11) % | ||||
| Current Valuation | 1.51 B | ||||
| Shares Outstanding | 118.64 M | ||||
| Price To Book | 10.31 X | ||||
| Price To Sales | 7.74 X | ||||
| Revenue | 196.54 M | ||||
| Gross Profit | 177.41 M | ||||
| EBITDA | (109.62 M) | ||||
| Net Income | (140.04 M) | ||||
| Cash And Equivalents | 282.17 M | ||||
| Cash Per Share | 5.47 X | ||||
| Total Debt | 3.38 M | ||||
| Debt To Equity | 0.40 % | ||||
| Current Ratio | 10.75 X | ||||
| Book Value Per Share | 1.34 X | ||||
| Cash Flow From Operations | (112.16 M) | ||||
| Earnings Per Share | (1.16) X | ||||
| Market Capitalization | 1.52 B | ||||
| Total Asset | 348.89 M | ||||
| Retained Earnings | (1.12 B) | ||||
| Working Capital | 254.81 M | ||||
| Current Asset | 87.18 M | ||||
| Current Liabilities | 4.42 M | ||||
About Arcutis Biotherapeutics Performance
Assessing Arcutis Biotherapeutics' fundamental ratios provides investors with valuable insights into Arcutis Biotherapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Arcutis Biotherapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 277.18 | 263.33 | |
| Return On Tangible Assets | (0.41) | (0.43) | |
| Return On Capital Employed | (0.48) | (0.50) | |
| Return On Assets | (0.40) | (0.42) | |
| Return On Equity | (0.89) | (0.93) |
Things to note about Arcutis Biotherapeutics performance evaluation
Checking the ongoing alerts about Arcutis Biotherapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Arcutis Biotherapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Arcutis Biotherapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 196.54 M. Net Loss for the year was (140.04 M) with profit before overhead, payroll, taxes, and interest of 177.41 M. | |
| Arcutis Biotherapeutics currently holds about 282.17 M in cash with (112.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.47. | |
| Arcutis Biotherapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Arcutis Biotherapeutics, Inc. Just Reported Yearly Earnings Have Analysts Changed Their Mind On The Stock |
- Analyzing Arcutis Biotherapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Arcutis Biotherapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Arcutis Biotherapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Arcutis Biotherapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Arcutis Biotherapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Arcutis Biotherapeutics' stock. These opinions can provide insight into Arcutis Biotherapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Arcutis Stock Analysis
When running Arcutis Biotherapeutics' price analysis, check to measure Arcutis Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcutis Biotherapeutics is operating at the current time. Most of Arcutis Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Arcutis Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcutis Biotherapeutics' price. Additionally, you may evaluate how the addition of Arcutis Biotherapeutics to your portfolios can decrease your overall portfolio volatility.